Market Overview

UPDATE: Canaccord Assumes Coverage on Optimer Pharmaceuticals

Related OPTR
HSR Waiting Period Expires for Cubist, Optimer Deal
Cubist Pharma Reports Pricing of $700M in Convertible Senior Notes, Expecting Proceeds of $679M

In a report published on Thursday, Canaccord assumed coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Buy rating and a $21 price target.

In the report Canaccord stated, “Assuming coverage with BUY rating, $21 target on expectation of steady revenue growth driven by unmet need and Dificid's superior efficacy in Clostridium difficile- efficacy in Clostridium difficile---associated diarrhea (CDAD). We feel there is still unmet need given the relapse rates associated with other therapies, the rising incidence of CDAD, and the growing severity of the disease. Further, we think the pharmaco-economics of Dificid treatment will drive uptake over time, despite premium pricing. Our $21 target is based on a DCF of Dificid/Dificlir sales and royalties.”

Optimer closed at $15.03 on Wednesday.

Latest Ratings for OPTR

DateFirmActionFromTo
Jul 2013Canaccord GenuityDowngradesBuyHold
Jul 2013JefferiesDowngradesBuyHold
May 2013NeedhamDowngradesBuyHold

View More Analyst Ratings for OPTR
View the Latest Analyst Ratings

Posted-In: CanaccordAnalyst Color Initiation Analyst Ratings

 

Related Articles (OPTR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters